New drug trial targets painful skin condition
NCT ID NCT06374212
Summary
This study is testing whether anifrolumab, an existing immune-system drug, can help control hidradenitis suppurativa (HS), a chronic inflammatory skin condition. Fifteen adults with moderate-to-severe HS will receive the drug intravenously over 24 weeks, followed by monitoring. Researchers will measure if it safely reduces painful skin lesions by at least 50% and improves patients' quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UNC Dermatology and Skin Cancer Center
Chapel Hill, North Carolina, 27516, United States
Conditions
Explore the condition pages connected to this study.